Comparative Pharmacology
Head-to-head clinical analysis: DURICEF versus KEFLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURICEF versus KEFLIN.
DURICEF vs KEFLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
500 mg to 1 g orally once or twice daily.
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
1.5-2 hours (prolonged to 20-30 hours in severe renal impairment; dosing adjustment required for CrCl <50 mL/min).
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); <10% biliary/fecal.
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic